阿斯利康宣布创新药英卓凡正式在中国上市

南方财经网08-04

南方财经8月4日电，阿斯利康宣布创新药物英卓凡®（英文商品名：Imjudo®，中文通用名：曲麦利尤单抗）正式在中国上市。今年4月，基于全球III期HIMALAYA研究及中国队列的积极结果，曲麦利尤单抗联合英飞凡®（中文通用名：度伐利尤单抗）在中国获批，用于晚期或不可切除的肝细胞癌（HCC）成人患者的一线治疗。此次曲麦利尤单抗正式上市，标志着这款拥有全球长期生存随访数据的创新疗法从临床研究步入临床...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2656585753?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-04 09:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2656585753","market":"sh","top_or_hot":-1,"title":"阿斯利康宣布创新药英卓凡正式在中国上市","media":"南方财经网","content":"<div>\n<p>南方财经8月4日电，阿斯利康宣布创新药物英卓凡®（英文商品名：Imjudo®，中文通用名：曲麦利尤单抗）正式在中国上市。今年4月，基于全球III期HIMALAYA研究及中国队列的积极结果，曲麦利尤单抗联合英飞凡®（中文通用名：度伐利尤单抗）在中国获批，用于晚期或不可切除的肝细胞癌（HCC）成人患者的一线治疗。此次曲麦利尤单抗正式上市，标志着这款拥有全球长期生存随访数据的创新疗法从临床研究步入临床...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202608043830619273.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>阿斯利康宣布创新药英卓凡正式在中国上市</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n阿斯利康宣布创新药英卓凡正式在中国上市\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-04 09:20 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202608043830619273.html><strong>南方财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>南方财经8月4日电，阿斯利康宣布创新药物英卓凡®（英文商品名：Imjudo®，中文通用名：曲麦利尤单抗）正式在中国上市。今年4月，基于全球III期HIMALAYA研究及中国队列的积极结果，曲麦利尤单抗联合英飞凡®（中文通用名：度伐利尤单抗）在中国获批，用于晚期或不可切除的肝细胞癌（HCC）成人患者的一线治疗。此次曲麦利尤单抗正式上市，标志着这款拥有全球长期生存随访数据的创新疗法从临床研究步入临床...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202608043830619273.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LNGR","symbol_name":"Global X Longevity Thematic ETF","start_time":0,"source_url":"http://finance.eastmoney.com/a/202608043830619273.html","article_id":"2656585753","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608043830619273.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2656585753","pubTimestamp":1785806400,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"南方财经8月4日电，阿斯利康宣布创新药物英卓凡?（英文商品名：Imjudo?，中文通用名：曲麦利尤单抗）正式在中国上市。今年4月，基于全球III期HIMALAYA研究及中国队列的积极结果，曲麦利尤单抗联合英飞凡?（中文通用名：度伐利尤单抗）在中国获批，用于晚期或不可切除的肝细胞癌（HCC）成人患者的一线治疗。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","LNGR":"Global X Longevity Thematic ETF","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","AZNH":"ASTRAZENECA PLC ADRhedged","BK4585":"ETF&股票定投概念","AZN":"阿斯利康","BK1574":"生物医药B类股","LU0058720904.USD":"联博国际健康护理基金A","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","IBBQ":"Invesco Nasdaq Biotechnology ETF","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","IPOS":"Renaissance International IPO ETF","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","BK4568":"美国抗疫概念","BK4588":"碎股","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","MEDX":"HORIZON KINETICS MEDICAL ETF","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","BK4007":"制药","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","06978":"永泰生物-B","BK1161":"生物科技","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"translate_title":"AstraZeneca announces the official launch of the innovative drug Yingzhuofan in China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1.5,"MEDX":1.5,"IBBQ":1.5,"LNGR":1.5,"IPOS":1.5,"AZN":1.5,"AZNH":0.6,"06978":1.5},"content_text":"南方财经8月4日电，阿斯利康宣布创新药物英卓凡®（英文商品名：Imjudo®，中文通用名：曲麦利尤单抗）正式在中国上市。今年4月，基于全球III期HIMALAYA研究及中国队列的积极结果，曲麦利尤单抗联合英飞凡®（中文通用名：度伐利尤单抗）在中国获批，用于晚期或不可切除的肝细胞癌（HCC）成人患者的一线治疗。此次曲麦利尤单抗正式上市，标志着这款拥有全球长期生存随访数据的创新疗法从临床研究步入临床应用，助力中国晚期肝癌患者向长期生存的目标迈出坚实一步。（21世纪经济报道）（文章来源：南方财经网）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2656585753","isCrawlerRequest":true}